mitobronitol

Mitobronitol is a brominated analog of mannitol and functions as an anticancer drug classified as an alkylating agent. Its mechanism of action involves the alkylation of DNA via derived epoxide groups, leading to DNA cross-linking and damage that disrupts replication and transcription processes. This ultimately results in cell cycle arrest and apoptosis. Mitobronitol has been investigated primarily for its antineoplastic activity, especially in chronic myelogenous leukemia (CML), with clinical trials conducted mainly using the oral formulation[1][2][4][5][6]. It is structurally related to other carbohydrate-derived cytostatic agents such as dibromodulcitol but differs in its activity spectrum and toxicity profile.

Brand names

Myelobromol

Other names

mitobronitoldibromomannitol1,6-dibromo-1,6-dideoxy-D-mannitol